However, the study also declared that the IL-22-mediated inhibition of liver fibrosis could not be completely mediated via its hepatoprotective effects because IL-22 liver-specific transgenic (IL-22TG) mice displayed a similar extent of liver injury after chronic CCl4-treatment when compared with wild-type (WT) mice [31]. Here, IL22 is linked to Hepatic fibrosis.